D-Glucosamine-6-phosphate (hydrate)
(Synonyms: D-GlcN-6-P) 目录号 : GC47206具有多种生物活性的神经肽
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
D-Glucosamine-6-phosphate (D-GlcN-6-P) is a monosaccharide intermediate of the hexosamine biosynthetic pathway.1 It is formed from D-fructose-6-phosphate by glucosamine-6-phosphate synthase (GlmS) in the presence of glutamine or from D-glucosamine by N-acetyl-D-glucosamine (GlcNAc) kinase.2,3,4 D-GlcN-6-P binds the GlmS riboswitch (Ki = 380 µM), a ribozyme located in the 5'-UTR of the gene encoding GlmS that, when bound by D-GlcN-6-P, inhibits GlmS production and decreases D-GlcN-6-P levels.2,5 It is a precursor in the biosynthesis of uridine diphosphate-N-acetylglucosamine (UDP-GlcNAc), a substrate for protein glycosylation and a component of bacterial cell walls.4,6
1.Buse, M.G.Hexosamines, insulin resistance, and the complications of diabetes: Current statusAm. J. Physiol. Endocrinol. Metab.290(1)E1-E8(2006) 2.Bearne, S.L., and Blouin, C.Inhibition of Escherichia coli glucosamine-6-phosphate synthase by reactive intermediate analogues. The role of the 2-amino function in catalysisJ. Biol. Chem.275(1)135-140(2000) 3.Akella, N.M., Ciraku, L., and Reginato, M.J.Fueling the fire: Emerging role of the hexosamine biosynthetic pathway in cancerBMC Biol.17(1)52(2019) 4.Chiaradonna, F., Ricciardiello, F., and Palorini, R.The nutrient-sensing hexosamine biosynthetic pathway as the hub of cancer metabolic rewiringCells7(6)53(2018) 5.Cochrane, J.C., Lipchock, S.V., and Strobel, S.A.Structural investigation of the GlmS ribozyme bound to its catalytic cofactorChem. Biol.14(1)97-105(2007) 6.RodrÍguez-DÍaz, J., Rubio-Del-Campo, A., and Yebra, M.J.Regulatory insights into the production of UDP-N-acetylglucosamine by Lactobacillus caseiBioengineered3(6)339-342(2012)
| Cas No. | N/A | SDF | |
| 别名 | D-GlcN-6-P | ||
| Canonical SMILES | OP(OC[C@H]([C@H]([C@@H]([C@H](C=O)N)O)O)O)(O)=O.O | ||
| 分子式 | C6H14NO8P.XH2O | 分子量 | 259.2 |
| 溶解度 | PBS (pH 7.2): 10mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.858 mL | 19.2901 mL | 38.5802 mL |
| 5 mM | 0.7716 mL | 3.858 mL | 7.716 mL |
| 10 mM | 0.3858 mL | 1.929 mL | 3.858 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。